Kurzfassung

A randomized, double-blind, placebo-controlled, multicenter, 28-week
treatment study with an 8 week follow-up period to investigate the impact
of subcutaneous omalizumab on quality of life measures as well as the
incidence and severity of angioedema in patients with chronic
spontaneaus urticaria having a history of angioedema despite Hlantihistamine
therapy